Amicus Briefs

When a court considers a case whose outcome may affect consumers or competition, the FTC may file a “friend of the court” brief to provide information that can help the court make its decision in a way that protects consumers or promotes competition. To find a specific FTC brief, use the filters on this page.

Displaying 81 - 100 of 111


Haese v. H & R Block, Inc.,

Citation Number: CV-96-423
Amicus brief addressing proposed class action settlement, advising the court of the Commission's views on the difficulty of assessing the value of class relief based on coupons, and the need to evaluate the high level of attorney's fees requested here ($49 million) in light of the actual benefit to consumers and the likely strength of the consumers' claims.

Dee-K Enterprises, Inc. v. Heveafil Sdn. Bhd.

Citation Number: 02-649
Federal Court: Supreme Court of the United States
Joint amicus brief of the United States and the Federal Trade Commission, urging the Court to deny the petition for certiorari. The brief explains that, although the court of appeals applied the wrong test in concluding that the Sherman Act did not apply to a global price-fixing conspiracy, the case is not appropriate for plenary review in light of the insufficient development of the record below and the absence of any conflict in the circuits on the questions presented.

Verizon Communications Inc. v. Law Offices of Curtis V. Trinko, LLP

Citation Number: 02-682
Federal Court: Supreme Court of the United States
Joint amicus brief of the United States and the Federal Trade Commission, urging reversal of the court of appeals' ruling, which had permitted a case to go forward under Section 2 of the Sherman Act, based on "essential facilities" and "monopoly leveraging" theories, despite the failure of plaintiff to allege exclusionary conduct under general Section 2 principles.

Empagran S.A. v. F. Hoffmann-LaRoche, Ltd.

Citation Number: 01-7115
Federal Court: U.S. Circuit Court of Appeals for the D.C. Circuit
Joint brief of the United States and the Federal Trade Commission, as amici curiae, addressing the proper application of the Foreign Trade Antitrust Improvements Act where a foreign plaintiff's claimed injury from an alleged antitrust conspiracy does not arise from the effects of that conspiracy on U.S. commerce.

SmithKline Beecham Corp. v. Apotex Corp.

Citation Number: 99-CV-4304
Federal Court: Eastern District of Pennsylvania

Memorandum of the Federal Trade Commission, as amicus curiae, addressing the propriety of de-listing a patent from FDA's "Orange Book," as a remedy for patent invalidity. The brief explains that improperly-maintained Orange Book listings may serve as a barrier to competition, and that there may be substantial consumer benefits to a de-listing remedy.

Powers v. Harris

Citation Number: CIV-01-445-F
Memorandum of the Federal Trade Commission, as amicus curiae, submitted to the United States District Court for the Western District of Oklahoma, in a case challenging Oklahoma state restrictions on the sale of caskets. The memorandum does not take a position on the constitutionality of those restrictions, but explains why the policies of the Commission's Funeral Rule do not lend support to restrictions of this sort.

George Carter, et al. v. ICR Services, Inc., d/b/a National Credit Repair

Federal Court: Northern District of Alabama

Amicus brief objecting to the proposed settlement’s claims process and the size of the proposed counsel fee in a case involving the allegedly deceptive marketing of credit repair services. The Commission argued that the claims process was unfair to certain class members and that the proposed legal fee for class counsel was excessive and would deplete the defendants’ resources and affect the FTC’s ability to obtain redress in its own broader case.

American Bioscience v. Bristol-Myers

Citation Number: CV-00-08577 WMB
Amicus brief before the U.S. District Court for the Central District of California regarding a proposed settlement between American Bioscience, Inc. (ABI) and Bristol-Myers Squibb Co. regarding the listing of a patent purportedly covering the cancer drug Taxol on the Food and Drug Administration’s Orange Book. The brief advises the court that, because the Commission had just initiated an investigation of the conduct of ABI and Bristol, the Commission was not taking a position with regard to appropriateness of listing the patent. The brief further explains the potential consequences of the proposed settlement on generic entry and the potential harm to consumers of delaying such entry. The brief expresses concern that the judicial finding that the settlement contemplates — that the patent meets the statutory requirements for listing in the Orange Book — will prejudice parties who may later challenge the listing. The brief requests the court to consider the ramifications for generic entry and the pendency of the Commission’s investigation before entering the order proposed by the parties.

Armstrong Surgical Center, Inc., Petitioner v. Armsrong County Memorial Hospital, et al.

Citation Number: 99-905

Amicus brief for the United States and the Federal Trade Commission urging denial of Supreme Court review in a case raising the issue whether misrepresentations to state agency, in the course of petitioning activity, precludes a claim of immunity from antitrust liability.